Return to homepagePandemic Pact

Antibody-enhanced COVID-19 vaccination

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $627,593.62

  • Funder

    Academy of Finland

  • Principal Investigator

    Marko Salmi

  • Research Location

    Finland

  • Lead Research Institution

    University of Turku

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Vaccine design and administration

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older), Older adults (65 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

A major challenge in COVID-19 vaccinations is to induce robust and good-quality protective immunity, especially in older persons. We will use a clinically approved therapeutic antibodies to overcome these limitations in experimental models. By co-injecting small quantities of immunomodulatory antibodies with the with a vaccine antigen we will revive the COVID-19 vaccine responses in aged immune system, and re-direct the anti-vaccine immune response to the most beneficial protecting direction. Our conceptually new way of using accepted therapeutic antibodies as COVID-19 vaccine adjuvants has the potential to generate more effective vaccine responses with less adverse effects, substantial vaccine-sparing and the protection of older individuals.